Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD2 reports from 2 outlets in 1 language · first reported 2026-10-01 11:30 UTC · updated 2026-10-01 11:40 UTC · JSONScience & technologyWave Life SciencesUnited States Food and Drug Administrationalpha-1-antitrypsin deficiencyReportsWave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATDPublished by manilatimes.net, GlobeNewswire — public companies · 2026-10-01 11:40 UTC